Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-932 in Depressive Episodes Associated With Bipolar I or II Disorder
NCT07220460Phase 2Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Sep 2025
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of ABBV-932 in bipolar disorder (BD), sponsored by AbbVie Inc.. Started Sep 2025; status: active, not recruiting.
02
Drugs
ABBV-932
03
Conditions
bipolar disorder (BD)
Beyond the preview
Go deeper on NCT07220460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07220460.